Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

Phase 2 Unknown 46 enrolled Sun Yat-sen University

RandomizedSingle-groupOpen-labelPrevention

Summary

This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma

Timeline

Start: 2021-04
Primary completion: 2023-04
Completion: 2023-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avatrombopag	Small molecule	60 mg	Oral

Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

Summary

Timeline

Drugs

Indications